Eylea vs Lucentis for Treatment-Naive Neovascular AMDEylea vs Lucentis for Treatment-Naive Neovascular AMD
A new study compares outcomes between these two drugs in previously untreated patients with neovascular AMD. How do they stack up? BMC Ophthalmology (Source: Medscape Ophthalmology Headlines)
Source: Medscape Ophthalmology Headlines - October 5, 2015 Category: Opthalmology Tags: Ophthalmology Journal Article Source Type: news
Anti-VEGF Therapy Before Steroids for Retinal Vein OcclusionAnti-VEGF Therapy Before Steroids for Retinal Vein Occlusion
Aflibercept and ranibizumab should be the first-line options in the treatment of central retinal vein occlusion, according to one small study. Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 21, 2015 Category: Consumer Health News Tags: Ophthalmology News Source Type: news
'Encouraging' Real-life Data on Ranibizumab in Wet AMD'Encouraging' Real-life Data on Ranibizumab in Wet AMD
Most patients with age-related macular degeneration (AMD) in a 'real-life' study maintained their vision or continued to improve after 5 years of treatment with ranibizumab. Medscape Medical News (Source: Medscape Ophthalmology Headlines)
Source: Medscape Ophthalmology Headlines - September 18, 2015 Category: Opthalmology Tags: Ophthalmology News Source Type: news
Effectiveness and Costs of Bevacizumab vs Ranibizumab in DMEEffectiveness and Costs of Bevacizumab vs Ranibizumab in DME
A new head-to-head trial compares the efficacy and economic value of these two anti-VEGF agents for DME. Which one has the edge? BMC Ophthalmology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 7, 2015 Category: Consumer Health News Tags: Ophthalmology Journal Article Source Type: news
Intas cuts Razumab supplies after adverse eye reactions
Razumab, a biosimilar of Genentech’s Lucentis, was launched in June at about 25 per cent cheaper than the innovator drug marketed by Novartis. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - August 20, 2015 Category: Pharmaceuticals Source Type: news
Ranibizumab for Neovascular AMD in Eyes With Good VisionRanibizumab for Neovascular AMD in Eyes With Good Vision
Starting ranibizumab treatment for neovascular AMD in eyes with good baseline visual acuity may provide additional benefits to visual outcomes. The British Journal of Ophthalmology (Source: Medscape Ophthalmology Headlines)
Source: Medscape Ophthalmology Headlines - August 20, 2015 Category: Opthalmology Tags: Ophthalmology Journal Article Source Type: news
Endophthalmitis Risk No Greater With Avastin Than Lucentis Endophthalmitis Risk No Greater With Avastin Than Lucentis
FDA-proposed restrictions on the ophthalmic use of bevacizumab through compounding pharmacies may be unnecessary, researchers find. Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 17, 2015 Category: Consumer Health News Tags: Ophthalmology News Source Type: news
Eye Infection Risk Similar for Avastin, Lucentis Injections (CME/CE)
(MedPage Today) -- Calls FDA guidance limiting ophthalmic bevacizumab compounding into question (Source: MedPage Today Geriatrics)
Source: MedPage Today Geriatrics - August 14, 2015 Category: Geriatrics Source Type: news
Bevacizumab vs Ranibizumab for Macular Edema Due to BRVOBevacizumab vs Ranibizumab for Macular Edema Due to BRVO
How does treatment between these two anti-VEGF agents compare in terms of visual acuity and central retinal thickness outcomes? The British Journal of Ophthalmology (Source: Medscape Ophthalmology Headlines)
Source: Medscape Ophthalmology Headlines - July 23, 2015 Category: Opthalmology Tags: Ophthalmology Journal Article Source Type: news
Squalamine Shows Promise in Retinal Vein OcclusionSqualamine Shows Promise in Retinal Vein Occlusion
The combination of topical squalamine and intravitreal ranibizumab appears to boost visual acuity more rapidly than ranibizumab alone in patients with retinal vein occlusion, a small study shows. Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 20, 2015 Category: Consumer Health News Tags: Ophthalmology News Source Type: news
Drug Dosages Questioned in Diabetic Macular Edema TrialDrug Dosages Questioned in Diabetic Macular Edema Trial
Experts wonder whether increased doses might eliminate the advantages seen with aflibercept over bevacizumab and ranibizumab in a diabetic macular edema trial. Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 18, 2015 Category: Consumer Health News Tags: Ophthalmology News Source Type: news
Ranibizumab Effective for Pigment Epithelial DetachmentRanibizumab Effective for Pigment Epithelial Detachment
Detachments of any size can effectively be treated with low-dose ranibizumab in patients with neovascular age-related macular degeneration, new research shows. Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 18, 2015 Category: Consumer Health News Tags: Ophthalmology News Source Type: news
Dexamethasone Implant as Adjunct Therapy for Wet AMDDexamethasone Implant as Adjunct Therapy for Wet AMD
Are there benefits to augmenting ranibizumab therapy with dexamethasone intravitreal implant treatment in patients with refractory wet AMD? The British Journal of Ophthalmology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 29, 2015 Category: Consumer Health News Tags: Ophthalmology Journal Article Source Type: news
Switching Anti-VEGF Agents in Treatment-Resistant Wet AMDSwitching Anti-VEGF Agents in Treatment-Resistant Wet AMD
Is aflibercept an effective therapeutic alternative for cases of wet AMD resistant to ranibizumab? BMC Ophthalmology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 12, 2015 Category: Consumer Health News Tags: Ophthalmology Journal Article Source Type: news
Ophthotech closes recruitment in first Phase III trial of Fovista/ Lucentis combination
Ophthotech has completed patient recruitment in its first Phase III trial of Fovista in combination with anti-VEGF agent Lucentis (ranibizumab) in wet age-related macular degeneration (AMD) programme. (Source: Drug Development Technology)
Source: Drug Development Technology - May 10, 2015 Category: Pharmaceuticals Source Type: news
